Search results for "Carbonic Anhydrase Inhibitors"

showing 7 items of 17 documents

Nitric oxide modulates cerebral blood flow stimulation by acetazolamide in the rat cortex: a laser Doppler scanning study

2001

Abstract The involvement of nitric oxide (NO) in cerebral blood flow (CBF) stimulation by acetazolamide was studied in anaesthetised, mechanically ventilated Wistar rats. CBF was monitored by laser Doppler scanning. Acetazolamide induced a long-lasting significant rCBF-increase. Application of N G -Nitro- l -arginine (L-NNA), an inhibitor of all NO synthetases (NOS), prevented CBF stimulation by acetazolamide. Continuous infusion of the exogenous NO donor SIN-1 (3-morpholinosydnonimine) suppressed L-NNA induced increases of mean arterial blood pressure without effect on rCBF in comparison to baseline. Additional acetazolamide injection then again caused a significant increase of rCBF in spi…

MaleArginineVasodilator AgentsHemodynamicsBlood PressureStimulationPharmacologyNitric OxideNitroarginineNitric oxidechemistry.chemical_compoundLaser-Doppler FlowmetrymedicineAnimalsNitric Oxide DonorsRats WistarCarbonic Anhydrase InhibitorsCerebral CortexChemistryGeneral NeuroscienceLaser Doppler velocimetryRatsAcetazolamidemedicine.anatomical_structurenervous systemCerebral blood flowCerebral cortexCerebrovascular CirculationMolsidomineAnesthesiaNitric Oxide SynthaseAcetazolamidecirculatory and respiratory physiologymedicine.drugNeuroscience Letters
researchProduct

Acetazolamide treatment for infantile central sleep apnea.

2001

Central sleep apnea is a common respiratory pattern in healthy neonates. Nevertheless, frequent central sleep apnea associated with drops in oxygen saturation may contribute to infantile morbidity. Recently, low-dose acetazolamide was shown to reduce symptomatic central sleep apnea in adults. We treated 12 infants, median conceptional age 42 weeks (range, 40-44 weeks), with central sleep apnea. In all cases, the central apnea index was >40/h total sleeping time (apnea ≥ 3 sec). The cumulative duration of drops in oxygen saturation below 90% was more than 3 min/h total sleeping time. All individuals received acetazolamide 7 mg/kg/day (orally, divided in three doses) for 11 weeks. Polysomn…

MaleCentral sleep apneaPolysomnographyPolysomnography030226 pharmacology & pharmacyDrug Administration ScheduleHypoxemia03 medical and health sciences0302 clinical medicineSleep Apnea SyndromesmedicineHumansOximetryRespiratory systemCarbonic Anhydrase InhibitorsOxygen saturation (medicine)medicine.diagnostic_testbusiness.industry05 social sciencesInfant Newborn050301 educationSleep apneaApneamedicine.diseaseAcetazolamideAnesthesiaPediatrics Perinatology and Child HealthFemaleNeurology (clinical)medicine.symptombusinessAcetazolamide0503 educationmedicine.drugJournal of child neurology
researchProduct

The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors.

2013

Purpose: To describe the study design and baseline factors of the Heidelberg Retina Tomograph ancillary study within the EGPS. Furthermore, to examine the relationship between HRT optic disc topographic measurements and baseline demographic and ocular factors. Methods: Four hundred and eighty-nine ocular hypertensive participants were included. Each participant completed HRT imaging at least annually. The associations between HRT measurements and IOP, central corneal thickness (CCT), baseline photographic estimates of vertical CDR ratio (CDR), asymmetry between the two eyes in CDR ratio and baseline visual field indices were assessed using regression analysis. Results: Associations between …

MaleIntraocular pressureVisual acuitygenetic structuresOptic diskVisual AcuityOcular hypertensionGlaucomaOptic Nerve DiseasesMedicineHRT parameterCarbonic Anhydrase Inhibitorspattern standard deviationTomographySulfonamidesmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.anatomical_structureResearch DesignOptic nerveFemalemedicine.symptomHumanOptic discmedicine.medical_specialtyCarbonic Anhydrase Inhibitorscanning laser ophthalmoscopyOptic DiskVisual FieldThiophenesSulfonamideOphthalmoscopyTonometry OcularOptic Nerve DiseaseDouble-Blind MethodThiopheneOphthalmologymental disordersHumansIntraocular Pressurebusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmoscopyOphthalmologyOcular Hypertensionsense organsVisual Fieldsbusinesscentral corneal thickneActa ophthalmologica
researchProduct

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.

2019

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy. Methods: In this Phase 4, double-masked trial, patients aged ⩾18 years, with a mean intraocular pressure of ⩾19 and <32 mm Hg in at least one eye were randomized (1:1) to receive BBFC + PGA ( n = 96) or vehicle + PGA ( n = 92) for 6 weeks. The primary endpoint was the mean change in diurnal intraocular pressure from baseline (averaged over 09:00 and 11:00 h) at Week 6. Results: The mean diu…

Malemedicine.medical_specialtyOpen angle glaucomagenetic structuresFixed-dose combinationBrinzolamideThiazinesOcular hypertensionopen-angle glaucoma03 medical and health sciencesTonometry Ocular0302 clinical medicineTravoprostDouble-Blind Methodintraocular pressure reductionOphthalmologyOriginal Research ArticlesmedicineAdrenergic alpha-2 Receptor AgonistsHumansCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureAgedAged 80 and overSulfonamidesbusiness.industryprostaglandin analogsBrimonidineBrinzolamide/brimonidine fixed-dose combinationGeneral MedicineMiddle Agedmedicine.diseaseAdjuncteye diseasesOphthalmologyDrug CombinationsProstaglandin analogBrimonidine Tartrate030221 ophthalmology & optometryLatanoprostocular hypertensionFemalesense organsbusiness030217 neurology & neurosurgeryGlaucoma Open-Anglemedicine.drugEuropean journal of ophthalmology
researchProduct

Bis(diethylenetriamine-κ3N)nickel(II) 5-amino-1,3,4-thiadiazole-2-sulfonamidate chloride monohydrate

2000

In the X-ray crystal structure of the title complex, [Ni(C(4)H(13)N(3))(2)](C(2)H(3)N(4)O(2)S(2))Cl.H(2)O, the coordination polyhedron is composed of non-centrosymmetric [Ni(diethylenetriamine)(2)](2+) cations in which the triamine ligands coordinate to the metal centre as tridentate ligands in a facial position. The Ni(II) ions are linked to six N atoms in an octahedral arrangement, slightly compressed in one extreme. The sulfonamide behaves as a counter-ion instead of as a ligand. Important information about the deprotonated sulfonamide group conformation has been obtained.

Models Molecularchemistry.chemical_classificationSulfonamidesStereochemistryLigandchemistry.chemical_elementHydrogen BondingGeneral MedicineCrystal structureCrystallography X-RayMedicinal chemistryGeneral Biochemistry Genetics and Molecular BiologySulfonamidechemistry.chemical_compoundNickelchemistryOctahedronDiethylenetriamineOrganometallic CompoundsAmine gas treatingDiazoCarbonic Anhydrase InhibitorsActa Crystallographica Section C Crystal Structure Communications
researchProduct

Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy

2017

Purpose Gyrate atrophy of the choroid and retina (GACR) is a rare chorioretinal dystrophy characterized by a deficiency of the enzyme ornithine aminotransferase, inherited in an autosomal recessive pattern. Case Report We report a case of a 17-year-old girl with GACR, for whom the level of serum ornithine had been reduced by an arginine-restricted diet. The patient was responsive to an association of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and a carbonic anhydrase inhibitor (CAI) to reduce cystoid macular edema (CME). Conclusions The efficacy of topical NSAIDs and systemic CAI association indicates that the imbalance in the distribution of retinal pigment epithelium membrane-b…

OrnithinePathologygenetic structuresIndomethacinVisual AcuityAdministration OralAdministration Ophthalmic0302 clinical medicineNonsteroidal anti-inflammatory drugCarbonic anhydrase inhibitorCarbonic Anhydrase Inhibitorschemistry.chemical_classificationOrnithine-Oxo-Acid TransaminaseAnti-Inflammatory Agents Non-SteroidalGeneral Medicinemedicine.anatomical_structureDrug Therapy CombinationFemaleTomography Optical CoherenceHumanmedicine.medical_specialtyAdolescentCarbonic Anhydrase Inhibitormedicine.drug_classOrnithine aminotransferaseeducationGyrate atrophy of the choroid and retinaOphthalmic Solution03 medical and health sciencesAtrophyGyrate atrophyInternal medicinemedicineHumansGyrate AtrophyMacular edemaRetinaMacular edemabusiness.industrymedicine.diseaseAcetazolamideOphthalmologyEnzymeEndocrinologychemistry030221 ophthalmology & optometrysense organsChoroidOphthalmic Solutionsbusiness030217 neurology & neurosurgery
researchProduct

Salts of 5-amino-2-sulfonamide-1,3,4-thiadiazole, a structural and analog of acetazolamide, show interesting carbonic anhydrase inhibitory properties…

2015

Three salts of 5-amino-2-sulfonamide-1,3,4-thiadiazole (Hats) were prepared and characterized by physico-chemical methods. The p-toluensulfonate, the methylsulfonate, and the chlorhydrate monohydrate salts of Hats were evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors (CAIs) and as anticonvulsants and diuretics, since many CAIs are clinically used as pharmacological agents. The three Hats salts exhibited diuretic and anticonvulsant activities with little neurotoxicity. The human (h) isoforms hCA I, II, IV, VII, IX, and XII were inhibited in their micromolar range by these salts, whereas pathogenic beta and gamma CAs showed similar, weak inhibitory profiles.

medicine.medical_treatmentPharmacology01 natural sciencesIsozymeThiadiazolesCarbonic anhydraseThiadiazolesDrug DiscoverymedicineHumansCarbonic Anhydrase InhibitorsDiureticsPharmacologySulfonamidesbiology010405 organic chemistryChemistrySulfonamide (medicine)NeurotoxicityGeneral Medicinemedicine.disease0104 chemical sciencesAcetazolamideIsoenzymes010404 medicinal & biomolecular chemistryAnticonvulsantbiology.proteinAnticonvulsantsDiureticAcetazolamidemedicine.drug
researchProduct